An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

For people with tough-to-treat epilepsy, seizures can be both frightening and dangerous, but a new experimental pill may bring significant relief to over one-third of them. Dubbed XEN1101, the new ...

SPI-1005 is the first drug to achieve its co-primary endpoints, involving clinically relevant improvements in PTA and WIN, in a pivotal Phase 3 randomized, double blinded, placebo-controlled trial ...

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Rachel L. Wasserman, PharmD, of the Department of General Internal Medicine at Brigham and Women's Hospital, is the lead author and David W. Bates, MD, medical director of Clinical and Quality ...